Provided in the present invention are a humanized monoclonal antibody for the 2019 novel coronavirus (2019-nCOV) and the use thereof. The antibody is capable of specifically binding with a receptor binding domain (RBD) of 2019-nCOV and blocking the binding between the RBD of 2019-nCOV and ACE2, and furthermore inhibiting the infection caused by 2019-nCOV.

A collection device for a biological sample to capture target compounds such as viruses or other pathogens or particles for testing from within the sample and move the captured target compound to a separate chamber for subsequent processing. The collection device can include an openable substance blister including capture particles located in a cup interior. Capture particles can attract and bind the target compounds from the sample. An extraction tube extracts any nucleic acid from the target compound for storage or subsequent amplification and testing to confirm presence of known microorganisms. The extraction tube can comprise a heat-deformable material and can be connected to a microfluidic cartridge for further processing of nucleic acid including, amplification and detection. The microfluidic cartridge includes valves and a plurality of chambers for amplification.

The present disclosure provides solution based assays for detecting antibodies induced by SARS-CoV-2 (anti-SARS-CoV-2) in a biological sample.

Embodiments of the present disclosure pertain to a sensor that includes a transduction agent, a plurality of analyte binding agents immobilized on the transduction agent, and a coating agent that forms a coating around at least some of the analyte binding agents. Further embodiments of the present disclosure pertain to methods of detecting one or more analytes in a sample by associating the sample with a sensor of the present disclosure; detecting a signal from the sensor; and correlating the signal to the presence or absence of the one or more analytes in the sample. Additional embodiments of the present disclosure pertain to methods of making the sensors of the present disclosure by immobilizing a plurality of analyte binding agents on a transduction agent; and coating at least some of the analyte binding agents with a coating agent to form a sensor.

Embodiments disclosed include systems, devices, and methods for analysis of samples containing particles used for gene delivery to determine a quality of the sample and/or an indication that the gene delivery particles are in a full, partial, and/or empty state. The present disclosure also relates to determining a protein and/or NA content in samples with known proportions of gene delivery particles in a full, partial, and/or empty state and based on the determination, establish a relationship between NA content and proportions of gene delivery particles in a full state. The present disclosure also relates to using such an established relationship to predict a proportion of the gene delivery particles in a full, partial, and/or empty state in test samples having the gene delivery particles in an unknown state.

Embodiments disclosed include systems, devices, and methods for analysis of samples containing particles used for gene delivery to determine a quality of the sample and/or an indication that the gene delivery particles are in a full, partial, and/or empty state. The present disclosure also relates to determining a protein and/or NA content in samples with known proportions of gene delivery particles in a full, partial, and/or empty state and based on the determination, establish a relationship between NA content and proportions of gene delivery particles in a full state. The present disclosure also relates to using such an established relationship to predict a proportion of the gene delivery particles in a full, partial, and/or empty state in test samples having the gene delivery particles in an unknown state.

The present disclosure relates to the field of virology. In particular, the disclosure teaches methods of detecting the presence of a respiratory viral infection (e.g. by a coronavirus or influenza virus) in a subject, and methods of treating said respiratory viral infection.

The present disclosure is directed to antibodies binding to and neutralizing Yellow Fever Virus and methods for use thereof.

Systems and methods are provided for detecting viral particles, viral proteins, viral RNA, or viral DNA in multiple fluids. The methods consist of applying a magnetic torque to functionalized magnetic beads in a fluid solution resting on a functionalized substrate. The solution is comprised of one of the following: intact viral particles, viral proteins, RNA, or DNA. The presence and/or quantity of the aforementioned molecules or viruses is detected by measuring the translational velocity of the beads. The methods here described can detect multiple different species simultaneously using a multiplexed assay. Also, the systems here included are able to process multiple samples simultaneously.

A rapid immunoassay method and apparatus for detecting foot and mouth disease virus are disclosed. The method and test device permit pen-side testing of animals and provide test results within a relatively short time period. In a preferred embodiment, the method and apparatus provide a means for differentiating between FMDV-infected and FMDV-vaccinated animals.